Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues

FDA’s Antiviral Drugs Advisory Committee will also assess whether existing data supports accelerated approval for the first-in-class HIV therapy.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet